Gene-drug interactions (data source: DGIdb)
Gene Name Entrez ID Drug Name Chembl ID Interaction Types Sources publications
FLT4 2324 SU-014813 CHEMBL1721885 inhibitor ChemblInteractions
FLT4 2324 AG-13958 CHEMBL3545335 inhibitor ChemblInteractions
FLT4 2324 FORETINIB CHEMBL1230609 inhibitor MyCancerGenome, GuideToPharmacologyInteractions, ChemblInteractions
FLT4 2324 Anlotinib CHEMBL3545021 inhibitor GuideToPharmacologyInteractions, ChemblInteractions
FLT4 2324 DOVITINIB CHEMBL522892 inhibitor TdgClinicalTrial, ClearityFoundationClinicalTrial, GuideToPharmacologyInteractions, ChemblInteractions
FLT4 2324 LENVATINIB CHEMBL1289601 inhibitor TALC, MyCancerGenome, TdgClinicalTrial, GuideToPharmacologyInteractions
FLT4 2324 MK-2461 CHEMBL1822792 inhibitor GuideToPharmacologyInteractions
FLT4 2324 SUNITINIB CHEMBL535 inhibitor TALC, TdgClinicalTrial, GuideToPharmacologyInteractions, TEND, DrugBank, MyCancerGenomeClinicalTrial 17605814, 16685460, 15688612, 17296815, 17367763
FLT4 2324 CEP-7055 CHEMBL346631 inhibitor ChemblInteractions
FLT4 2324 TELATINIB CHEMBL2079588 inhibitor TALC, MyCancerGenome, TdgClinicalTrial, ChemblInteractions
FLT4 2324 VANDETANIB CHEMBL24828 inhibitor TALC, TdgClinicalTrial, ClearityFoundationClinicalTrial, ChemblInteractions, MyCancerGenomeClinicalTrial
FLT4 2324 SU-14813 CHEMBL3545160 inhibitor ChemblInteractions
FLT4 2324 4SC-203 CHEMBL3545358 inhibitor ChemblInteractions
FLT4 2324 TAK-593 CHEMBL2180604 inhibitor ChemblInteractions
FLT4 2324 SORAFENIB CHEMBL1336 antagonist, inhibitor TALC, TdgClinicalTrial, TEND, DrugBank, MyCancerGenomeClinicalTrial 17296815, 16757355, 16474853, 16133532, 16729906
FLT4 2324 Fruquintinib CHEMBL3545339 inhibitor TdgClinicalTrial, GuideToPharmacologyInteractions, ChemblInteractions
FLT4 2324 NINTEDANIB CHEMBL502835 inhibitor, Inhibitor TALC, MyCancerGenome, TdgClinicalTrial, ClearityFoundationClinicalTrial, GuideToPharmacologyInteractions, DrugBank 18559524
FLT4 2324 TIVOZANIB CHEMBL1289494 inhibitor TALC, MyCancerGenome, TdgClinicalTrial, ClearityFoundationClinicalTrial, GuideToPharmacologyInteractions, ChemblInteractions
FLT4 2324 TG100-801 CHEMBL403989 DrugBank
FLT4 2324 IMC-1C11 CHEMBL2109257 DrugBank
FLT4 2324 AXITINIB CHEMBL1289926 inhibitor TALC, MyCancerGenome, TdgClinicalTrial, ChemblInteractions, DrugBank, CancerCommons, MyCancerGenomeClinicalTrial 18541897
FLT4 2324 ILORASERTIB CHEMBL1980297 inhibitor ChemblInteractions
FLT4 2324 CEP-11981 CHEMBL2010872 inhibitor ChemblInteractions
FLT4 2324 SUNITINIB MALATE CHEMBL1567 inhibitor ChemblInteractions
FLT4 2324 CHEMBL313417 CHEMBL313417 TdgClinicalTrial
FLT4 2324 CEP-5214 CHEMBL150894 inhibitor ChemblInteractions
FLT4 2324 CP-459632 CHEMBL3545300 inhibitor ChemblInteractions
FLT4 2324 Sulfatinib CHEMBL3545251 inhibitor ChemblInteractions
FLT4 2324 KRN-633 CHEMBL406381 inhibitor ChemblInteractions
FLT4 2324 L-21649 CHEMBL3544927 inhibitor ChemblInteractions
FLT4 2324 BMS-690514 CHEMBL3545396 inhibitor ChemblInteractions
FLT4 2324 MGCD-265 CHEMBL254760 inhibitor TALC, MyCancerGenome, TdgClinicalTrial, ChemblInteractions
FLT4 2324 SEMAXANIB CHEMBL276711 inhibitor ChemblInteractions
FLT4 2324 CEDIRANIB CHEMBL491473 inhibitor TALC, TdgClinicalTrial, ClearityFoundationClinicalTrial, GuideToPharmacologyInteractions, ChemblInteractions
FLT4 2324 CC-223 CHEMBL3545151 inhibitor GuideToPharmacologyInteractions
FLT4 2324 LINIFANIB CHEMBL223360 inhibitor MyCancerGenome, TdgClinicalTrial, GuideToPharmacologyInteractions, ChemblInteractions, DrugBank
FLT4 2324 PAZOPANIB CHEMBL477772 inhibitor TALC, MyCancerGenome, TdgClinicalTrial, GuideToPharmacologyInteractions, DrugBank, MyCancerGenomeClinicalTrial 17288876
FLT4 2324 VATALANIB CHEMBL101253 inhibitor MyCancerGenome, TdgClinicalTrial, GuideToPharmacologyInteractions, ChemblInteractions, DrugBank 17584317
FLT4 2324 REGORAFENIB CHEMBL1946170 inhibitor TALC, MyCancerGenome, ChemblInteractions, DrugBank, MyCancerGenomeClinicalTrial
FLT4 2324 ENMD-2076 CHEMBL482968 inhibitor MyCancerGenome, TdgClinicalTrial, ClearityFoundationClinicalTrial
FLT4 2324 PEGPLERANIB SODIUM CHEMBL3301576 TdgClinicalTrial
FLT4 2324 XL-999 CHEMBL3545285 inhibitor TdgClinicalTrial, ChemblInteractions
FLT4 2324 PAZOPANIB HYDROCHLORIDE CHEMBL1201733 inhibitor ChemblInteractions
FLT4 2324 TABERMINOGENE VADENOVEC CHEMBL2108065 TdgClinicalTrial
FLT4 2324 ORANTINIB CHEMBL274654 inhibitor MyCancerGenome
FLT4 2324 X-82 CHEMBL3545401 inhibitor MyCancerGenome, ChemblInteractions
FLT4 2324 NINTEDANIB ESYLATE CHEMBL3039504 inhibitor ChemblInteractions
FLT4 2324 BRIVANIB ALANINATE CHEMBL270995 inhibitor ChemblInteractions
FLT4 2324 MOTESANIB CHEMBL572881 inhibitor TALC, MyCancerGenome, TdgClinicalTrial, GuideToPharmacologyInteractions, ChemblInteractions
FLT4 2324 TESEVATINIB CHEMBL3544983 inhibitor MyCancerGenome, TdgClinicalTrial, GuideToPharmacologyInteractions
FLT4 2324 LENVATINIB MESYLATE CHEMBL2105704 inhibitor ChemblInteractions
FLT4 2324 Chiauranib CHEMBL3545428 inhibitor ChemblInteractions
FLT4 2324 JNJ-26483327 CHEMBL3545133 inhibitor ChemblInteractions
FLT4 2324 OSI-930 CHEMBL1614710 inhibitor ChemblInteractions
FLT4 2324 RG-1530 CHEMBL1980391 inhibitor ChemblInteractions
FLT4 2324 Famitinib CHEMBL3545026 inhibitor ChemblInteractions
FLT4 2324 BRIVANIB CHEMBL377300 inhibitor ChemblInteractions
FLT4 2324 SORAFENIB TOSYLATE CHEMBL1200485 inhibitor ChemblInteractions, MyCancerGenomeClinicalTrial
FLT4 2324 LUCITANIB CHEMBL2220486 inhibitor ChemblInteractions, MyCancerGenomeClinicalTrial
FLT4 2324 IMC-3C5 CHEMBL2109602 TdgClinicalTrial
FLT4 2324 XL-820 CHEMBL3545402 inhibitor TdgClinicalTrial, ChemblInteractions

Variant-drug associations (data source: PharmGKB)
Gene Name Variant Alleles Chemical Phenotype Category Significance Notes Sentence Publications Annotation ID
FLT4 rs307805 CC + CT cisplatin efficacy no No significant association was found in progression free survival or overall survival. Genotypes CC + CT are not associated with response to cisplatin, fluorouracil and oxaliplatin in people with Stomach Neoplasms as compared to genotype TT. 24090479 1183701031
FLT4 rs6877011 CG + GG cisplatin efficacy no No significant association was found in progression free survival or overall survival. Genotypes CG + GG are not associated with response to cisplatin, fluorouracil and oxaliplatin in people with Stomach Neoplasms as compared to genotype CC. 24090479 1183701035
FLT4 rs6877011 G imatinib dosage no No significant association between genotype and chance of requiring an imatinib dose reduction. Allele G is not associated with dose of imatinib in people with Gastrointestinal Stromal Tumors as compared to allele C. 30713339 1450933577
FLT4 rs307822 CT + TT cisplatin efficacy no No significant association was found in progression free survival or overall survival. Genotypes CT + TT are not associated with response to cisplatin, fluorouracil and oxaliplatin in people with Stomach Neoplasms as compared to genotype CC. 24090479 1183701027